RESEARCH

Interactive effects of intrinsic capacity and obesity on the KDIGO chronic kidney disease risk classification in older patients with type 2 diabetes mellitus

Wei-Hua Tang[1,2], Teng-Hung Yu[3,4], Hui-Lan Lee[5] and Yau-Jiunn Lee[6*]

Abstract

Background: Intrinsic capacity (IC) is a novel concept focusing on normal and healthy aging. The effect of IC on the risk of chronic kidney disease (CKD) according to KDIGO category in older type 2 diabetes mellitus (T2DM) patients has rarely been studied. We investigated whether a decline in IC is associated with the risk of CKD according to KDIGO 2012 categories.

Methods: This is a cross-sectional study. The exposure variables (IC score and body mass index) and outcome variable (KDIGO categories of the risk of CKD) were collected at the same timepoint. A total of 2482 older subjects with T2DM managed through a disease care program were enrolled. The five domains of IC, namely locomotion, cognition, vitality, sensory, and psychological capacity were assessed. Based on these domains, the IC composite score was calculated. CKD risk was classified according to the KDIGO 2012 CKD definition. Univariate and multivariate analyses were used to assess the association between IC score and KDIGO categories of risk of CKD.

Results: The KDIGO CKD risk category increased in parallel with IC score (p for trend < 0.0001). In multivariate analysis, compared to those with an IC score 0, the odds ratio of having a KDIGO moderately increased to very high risk category of CKD was 1.76 (1.31–2.37) times higher for those with an IC score of 2–5. Furthermore, an increased IC score was associated with a higher prevalence of moderate and severe obesity. Moreover, there was a synergistic interaction between IC score and obesity on the KDIGO moderately increased to very high risk category of CKD (synergy index = 1.683; 95% CI 0.630–3.628), and the proportion of the KDIGO moderately increased to very high risk category of CKD caused by this interaction was 25.6% (attributable proportion of interaction = 0.256).

Conclusions: Our findings indicate that IC score may be closely related to the KDIGO moderately increased to very high risk category of CKD. In addition, there may be a synergistic interaction between IC score and obesity, and this synergistic interaction may increase the KDIGO CKD risk stage.

Keywords: KDIGO chronic kidney disease risk classification, Intrinsic capacity, Obesity, Synergistic interaction, Type 2 diabetes mellitus

Background

The number of older people worldwide is projected to increase to over 1.5 billion within 30 years [1]. The incidence of diabetes mellitus (DM) is also increasing globally with the exponential increase in obesity [2]. Aging is

*Correspondence: lee@leesclinic.org

[6] Lee's Endocrinologic Clinic, No. 130 Min-Tzu Rd, Pingtung 90000, Taiwan
Full list of author information is available at the end of the article

Tang *et al. Diabetology & Metabolic Syndrome*   (2023) 15:1

Page 2 of 10

inevitable, and so how to maintain a healthy active lifestyle later in life has become an important issue, both for individuals and social-economic systems [3].

More than 40% of diabetic patients will develop diabetic kidney disease and renal impairment despite controlling serum glucose status and other risk factors such as blood pressure and metabolic syndrome [4, 5]. In the past decades, numerous risk factors have been associated with chronic kidney disease (CKD) progression, and they have been grouped into six categories: sociodemographic and economic, behavioral, genetic, cardiovascular, metabolic, and several novel acute kidney injury biomarkers [6]. Although many promising biomarkers for CKD diagnosis and progression have been identified, few have been implemented into routine clinical practice [7]. This is because the prevention of DM-related CKD is very complex, especially in older patients, and it involves many psychological, cognitive, and behavioral aspects in addition to blood pressure and glucose control [8–10].

Intrinsic capacity (IC), defined as the composite of an individual's mental and physical capacities and their interactions with relevant environmental characteristics, was introduced by the World Health Organization in 2015 [11]. IC measures the capacity of human biological and physiological systems, based on body and physical function [12]. Over time, IC may provide contextualized monitoring measurements which can then be used to inform clinical and public health policy [13]. Recent studies on IC have mainly focused on aging-related diseases, such as dementia [14, 15], and the use of IC in other diseases is rare. As impaired renal function always develops in older diabetic patients, the aim of this study was to evaluate the interactive effect of IC score and obesity on the KDIGO CKD risk classification among 2482 diabetic patients older than 65 years of age. To the best of our knowledge, this is the first study to apply the concept of IC to the KDIGO CKD risk classification in older DM patients.

Materials and methods
Study design and participants
Totally eight diabetes-specific local clinics in Southern Taiwan and the diabetic department of Kaohsiung E-Da Hospital, Taiwan jointed in this cross-sectional study. The exposure variables (IC score and body mass index (BMI)) and outcome variable (KDIGO categories of the risk of CKD) were collected at the same timepoint. A Total of 2482 older outpatient subjects with T2DM were enrolled. The inclusion criteria aged ≥ 65 years, clinically diagnosed with T2DM between January 2006 and October 2021, relatively healthy without acute illness and without evidence suggesting the possibility of a non-diabetic renal disease (included primary glomerular diseases, drug-induced nephropathy, reflux nephropathy, nephrolithiasis, polycystic kidney and renal-related infectious diseases). The exclusion criteria were patients: (1) aged < 65 years; (2) with type 1 diabetes; (3) with history with cancer, liver or urologic diseases; (4) who had been hospitalized for any reasons within 3 months prior to enrollment; (5) with recently use of allopurinol or uricosuric agents for gouty arthritis; (6) who underwent contrast examinations during the follow-up period; and (7) who could not provide complete demographics and personal medical information. In addition, to avoid the potential development/presence of primary glomerular diseases, we also excluded patients with persistent hematuria with and without urinary casts.

The diagnosis of T2DM was based on the World Health Organization criteria [16]. All of the patients were followed up in accordance with the diabetes comprehensive management program suggested by the Taiwan National Health Insurance at 3-month intervals. At each follow-up visit, standardized physical examinations, biochemical measurements after fasting, measurements of urine albumin and creatinine were performed. All participants received standard treatment based on recent updated diabetes, hypertension, and dyslipidemia management guidelines. All of the participants signed free and informed consent forms before enrollment into the study. Our study protocol and procedures were approved by E-Da Hospital Institutional Review Board with certificate number EMRP-108-111 and EMRP-109-109 and the Ethics Committees of Pingtung Christian Hospital with an approval certificate on 16 December 2005.

Key measures
IC was determined using the ICOPE (WHO) screening tools, including six functional assessments of the following five domains: locomotion, cognition, vitality, sensory (visual and sensory), and psychological symptoms [17]. If subject was unable to complete five chair rises within 14 s, limited locomotion mobility was defined. If the patients gave an inappropriate answer to either of two questions on orientation in time and space, or could not recall the three words they were asked to remember, impaired cognitive dysfunction was defined. If subject suffered from weight loss greater than 3 kg over 3 months or with the loss of appetite, malnutrition was defined. If subject had any eye problems such as difficulty in seeing far, reading, eye diseases, or current ophthalmic medical treatment, a visual impairment was defined. If subject failed to hear whispers in the whisper test, a hearing loss was defined. If subject bothered by feeling down, feeling depressed or hopeless, or having little interest or pleasure in doing things over the previous 2 weeks, a depressive symptom was suggested. Finally, impairment in each

Tang *et al. Diabetology & Metabolic Syndrome*   (2023) 15:1

Page 3 of 10

item was scored as one point, and IC score was defined as the sum of the six functional assessments, with a higher score indicating greater functional impairment.

Obesity was defined according to the Ministry of Health and Welfare, Taiwan, criteria instead of the WHO criteria, as it has been suggested that the WHO BMI cut-off point for obesity (≥ 30 kg/m^2) may be too high for Asians, thereby underestimating associated health risks [18, 19]. Accordingly, we defined underweight as BMI below 18.5 kg/m^2, normal weight as between $18.5 \leq BMI < 24$ kg/m^2, overweight as $24 \leq BMI < 27$ kg/m^2, mild obesity as $27 \leq BMI < 30$ kg/m^2, moderate obesity as $30 \leq BMI < 35$ kg/m^2, and severe obesity as BMI greater than 35 kg/m^2 [20].

Renal function (estimated glomerular filtration rate (eGFR)) was estimated using the CKD-EPI two-concentration race equation [21]: $GFR = 141 \times \min(S_{cr}/\kappa, 1)^{\alpha} \times \max(S_{cr}/\kappa, 1)^{-1.209} \times 0.993^{Age} \times 1.018$ [if female] $\times 1.159$ [if black], where S_{cr} is serum creatinine (mg/dL), κ is 0.7 if females and 0.9 if males, α is -0.329 if females and -0.411 if males, min indicates the minimum of S_{cr}/κ or 1, and max indicates the maximum of S_{cr}/κ or 1. Albuminuria was defined by the albumin-to-creatinine ratio (UACR) from spot urine. The presence of albuminuria was defined by at least two measurements of UACR > 30 mg/g in a 6-month period during follow-up. The outcome was the classification of the patients in 4 categories based on their risk for CKD according to KDIGO 2012 using a combination of eGFR and albuminuria as follows: low risk group (eGFR ≥ 60 mL/min/1.73 m^2 and UACR < 30 mg/g), moderately increased risk group (eGFR > 60 mL/min/1.73 m^2 and 30 < UACR < 300 mg/g, or 45 < eGFR < 60 mL/min/1.73 m^2 and 30 < UACR < 300 mg/g), high risk group (30 < eGFR < 60 mL/min/1.73 m^2 and UACR > 300 mg/g, or eGFR > 60 mL/min/1.73 m^2 and UACR > 300 mg/g), and very high risk group (15 < eGFR < 60 mL/min/1.73 m^2 and UACR > 300 mg/g, or eGFR < 15 mL/min/1.73 m^2 and UACR > 300 mg/g) [22].

Laboratory measurements

Routine tests including a clinical examination, recent medication side effect assessment, body weight, blood pressure, urinary sediment and urinalysis, complete blood count, serum chemistry, and HbA1c concentrations were performed during each regular visits. The urinary albumin concentration was measured after overnight fasting by immunoturbidimetry (Beckman Instruments, Galway, Ireland). The detection limit was 2 mg/L, with the interassay and intraassay coefficients of variance < 8%. In the study admission, the patients were defined as normoalbuminuric if they had a UACR < 30 mg/g in at least two consecutive overnight

urine collections. If the patient had first UACR measurement > 30 mg/g, a repeat urine test will be asked and checked to confirm the diagnosis of albuminuria within 3–6 months in the follow-up period later. If the urine specimen showed the presence of urinary infections, the specimen will not be used and a new sample was collected after antibiotics treatment. To exclude primary renal diseases, abnormal urinary sediment should not be noted in the urine specimen (presence of any protein, red blood cells, hemoglobin, white blood cells, nitrites or casts). Serum creatinine was measured by the Jaffe method. Serum HbA1C, total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides, hemoglobin, creatinine, and glucose were determined using a parallel-multichannel analyzer (Hitachi 7170A, Tokyo, Japan) by standard commercial methods after an overnight fast as in our previous report [23].

Variables

All participants completed a standard questionnaire that assessed age, gender, cigarette use, history of disease (T2DM, diabetes duration, hyperlipidemia, hypertension, heart disease, and cancer) in face-to-face interviews with trained interviewers. Subject's blood pressure was measured by trained clinical assistants with digital automatic blood pressure monitor (model HEM-907; Omron, Omron, Japan) after resting for 5 min. Hypertension was defined as a systolic blood pressure (SBP) ≥ 140 mmHg, a diastolic blood pressure (DBP) ≥ 90 mmHg, or if the patient was recent using antihypertensive medication. Anthropometric parameters including BMI (kg/m^2) were measured. Hyperlipidemia was defined according to the ATP III criteria as following: triglycerides ≥ 150 mg/dl, and/or HDL-C < 35 mg/dl in men or < 39 mg/dl in women, and/or total cholesterol ≥ 200 mg/dl, and/or LDL-C ≥ 130 mg/dl, or those undergoing treatment for lipid disorders.

Statistical analysis

Data normality was analyzed using the Kolmogorov–Smirnov test. Continuous, normally distributed variables are presented as mean ± SD, and non-normally distributed variables as median (interquartile range). Categorical variables are presented as frequencies and/or percentages. Baseline characteristics were compared between groups using one-way analysis of variance (ANOVA) for normally distributed variables. The chi-square test was used to compare categorical variables.

Logistic regression models were used to estimate odds ratios (ORs) and 95% confidence intervals (CIs) for the risk of CKD in each IC score, compared with an IC score of 0 as the reference. To test linear risk trends, a tertiles

Tang *et al. Diabetology & Metabolic Syndrome*   (2023) 15:1

Page 4 of 10

as a continuous variable in the regression models was used.

ORs and corresponding 95% CIs were calculated using univariate and multivariate logistic regression models to evaluate the relationships between IC scores and the risk of CKD. A p value < 0.05 was considered to be statistically significant. JMP version 7.0 for Windows (SAS Institute, Cary, NC, USA) was used in our analysis.

An Excel sheet provided by Andersson and co-authors [24] was used into the database and compute the relevant indicators of interactions. Using a logistic regression model, a value was obtained and taken as the estimated additive interaction between IC score and obesity status. The interaction based on the additive model was determined using the following indexes: the relative excess risk of interaction (RERI), attributable proportion of interaction (API), synergy index (SI), measure of multiplicative interaction for risk ratios [25] and their 95% CIs using the delta method [26]. The RERI refers to the excess risk due to the interaction relative to the risk without exposure. The API is the attributable proportion of disease caused by the interaction in subjects with both exposures. The SI refers to the excess risk from both exposures when there is a biological interaction due to the risk from both exposures without interaction. The RERI has been showed to be the best measure of interaction using a proportional hazards model [27]. If the RERI and AP are equal to 0, absence of additive interactions was defined [28]. Finally, an indicative biological interaction is considered when RERI > 0, AP > 0, S > 1, or a measure of multiplicative interaction for risk ratios > 1.

Results

Characteristics of the participants

A total of 2482 patients with T2DM aged 65–99 years were included, and their baseline characteristics and clinical data are presented in Table 1. The mean ± SD age was 72.4 ± 5.8 years and known duration of diabetes was 13.5 ± 9.0 years. The prevalence rates of hypertension, hyperlipidemia, and smoking were 62.5%, 78.8%, and 15.6%, respectively. The patient's mean eGFR was 68.9 ± 22.0 mL/min/1.73 m^2, and the median (interquartile range) UACR was 19.2 mg/g (9.7–54.3 mg/g).

Main characteristics according to IC score

Furthermore, the general characteristics of the 2482 patients grouped according to IC scores are also reported in Table 1. The numbers of patients with an IC score of 0, 1, and 2–5 were 1525 (61.4%), 655 (26.4%), and 302 (12.2%), respectively. The patients with an IC score 2–5 were more predominantly female, had severe obesity, higher prevalence of KDIGO high risk and very high risk categories of CKD, higher rates of both insulin and oral

hypoglycemic agents, older age, longer diabetes duration, higher HbA1c, fasting glucose, UACR, and creatinine levels, and lower prevalence of KDIGO low risk category of CKD, eGFR, and hemoglobin levels than those with an IC score of 0 or 1. Moreover, the patients with an IC score 2–5 had a higher prevalence of hypertension and moderate obesity, and higher rate of treatment with angiotensin receptor blockers than those with an IC score of 0. There were no significant differences in hyperlipidemia, current smoker, waist-to-hip ratio, SBP, DBP, underweight, normal weight, overweight, mild obesity, KDIGO moderately increased risk category of CKD, statin treatment, total cholesterol, triglycerides, HDL cholesterol, LDL cholesterol, and uric acid among the three groups.

Association between IC score and KDIGO moderately increased risk to very high risk category of CKD

We investigated associations between IC score and KDIGO moderately increased risk to very high risk category of CKD (Table 2). The KDIGO moderately increased risk to very high risk category of CKD increased in parallel with IC score. Accordingly, there were increases in the ORs for the association with KDIGO moderately increased risk to very high risk category of CKD relative to an IC score of 0, OR = 1.0; score 1, OR = 1.36; score 2–5, OR = 2.57 (p for trend across increasing IC scores < 0.0001).

Association of IC score with KDIGO moderately increased risk to very high risk category of CKD

We used univariate and multivariate logistic regression models to investigate associations between IC score and KDIGO moderately increased risk to very high risk category of CKD (Table 3). Patients with an IC score of 1 had an increased KDIGO moderately increased risk to very high risk category of CKD compared with those who had an IC score of 0 in model 1 and model 2. However, those with an IC score of 1 did not have an increased KDIGO moderately increased risk to very high risk category of CKD compared with those who had an IC score of 0 in model 3. Patients with an IC score of 2–5 had a higher KDIGO moderately increased risk to very high risk category of CKD compared with those with an IC score 0 in model 1, model 2, and model 3 (OR: 2.57, 95% CI 1.97–3.36, p < 0.0001, OR:1.82, 95% CI 1.38–2.42, p < 0.0001, and OR: 1.76, 95% CI 1.31–2.37, p = 0.0002, respectively).

Joint impacts of IC score and obesity on the KDIGO moderately increased risk to very high risk category of CKD

Because an increased IC score was associated with higher moderate and severe obesity, we investigated the additive interaction effect of IC score and moderate and severe obesity on the KDIGO moderately increased risk to very

Table 1 Main characteristics according to intrinsic capacity score

	Total	IC score 0	IC score 1	IC score ≥ 2	p-value
Number	2482	1525	655	302	
Age (years)	72.4 ± 5.8	71.2 ± 5.0	73.2 ± 5.9	77.0 ± 6.6	< 0.0001
Sex, female (n, %)	1374(55.4)	790(51.8)	393(60.0)	191(63.3)	< 0.0001
Diabetes duration (years)	13.5 ± 9.0	13.1 ± 8.8	13.7 ± 9.2	15.2 ± 9.2	0.001
Hypertension (n, %)	1552(62.5)	917(60.1)	438(66.9)	197(65.2)	0.007
Hyperlipidemia (n, %)	1956(78.8)	1217(79.8)	503(76.8)	236(78.2)	0.276
Current smoker (n, %)	486(19.6)	315(20.7)	121(18.5)	50(16.6)	0.184
Body mass index (kg/m^2)	25.6 ± 4.0	25.4 ± 3.8	26.0 ± 4.2	25.8 ± 4.2	0.001
Waist-to-hip ratio	0.93 ± 0.07	0.92 ± 0.07	0.93 ± 0.07	0.93 ± 0.07	0.156
SBP (mmHg)	129 ± 16	128 ± 15	130 ± 16	130 ± 19	0.076
DBP (mmHg)	73 ± 11	73 ± 11	73 ± 11	73 ± 11	0.669
Obesity status (n, %)					
Underweight	35(1.4)	19(1.3)	11(1.7)	5(1.7)	0.681
Normal weight	886(35.7)	571(37.4)	210(32.1)	105(34.8)	0.052
Overweight	782(31.5)	485(31.8)	199(30.4)	98(32.5)	0.752
Mild obesity	451(18.2)	278(18.2)	129(19.7)	44(14.6)	0.160
Moderate obesity	274(11.0)	147(9.6)	88(13.4)	39(12.9)	0.019
Severe obesity	54(2.2)	25(1.6)	18(2.8)	11(3.6)	0.047
KDIGO CKD risk stage (n, %)					
Low risk	1167(47.0)	789(51.7)	289(44.1)	89(29.5)	< 0.0001
Moderately increased risk	610(24.6)	379(24.9)	154(23.5)	77(25.5)	0.740
High risk	368(14.8)	192(12.6)	108(16.5)	68(22.5)	< 0.0001
Very high risk	337(13.6)	165(10.8)	104(15.9)	68(22.5)	< 0.0001
Type of treatment (%)					
(OHA/Insulin/Both)	67.8/3.2/29.1	71.6/2.1/26.3	65.5/4.6/30.0	53.7/5.3/41.0	< 0.0001
Statins (n, %)	1919(77.3)	1193(78.2)	494(75.4)	232(76.8)	0.348
ARB (n, %)	1085(43.7)	626(41.1)	317(48.4)	142(47.0)	0.003
Biochemical characteristics					
HbA1c (%)	7.3 ± 1.2	7.2 ± 1.1	7.2 ± 1.2	7.5 ± 1.4	0.006
Fasting glucose (mmol/L)	8.5 ± 3.4	8.4 ± 3.3	8.5 ± 3.4	8.9 ± 3.8	0.001
Total cholesterol (mmol/L)	4.1 ± 0.8	4.1 ± 0.8	4.1 ± 0.8	4.0 ± 0.8	0.671
Triglycerides (mmol/L)	1.3 ± 0.7	1.3 ± 0.8	1.3 ± 0.7	1.3 ± 0.6	0.694
HDL cholesterol (mmol/L)	1.4 ± 0.4	1.4 ± 0.4	1.4 ± 0.4	1.4 ± 0.4	0.986
LDL cholesterol (mmol/L)	2.1 ± 0.6	2.1 ± 0.6	2.1 ± 0.7	2.1 ± 0.6	0.503
Uric acid (mmol/L)	5.4 ± 1.6	0.3 ± 0.1	0.3 ± 0.1	0.3 ± 0.1	0.841
eGFR (ml/min/1.73m^2)	68.9 ± 22.0	77.2 ± 20.5	73.3 ± 21.5	71.0 ± 23.0	< 0.0001
UACR (mg/g)	19.2(9.7–54.3)	17.1(8.8–46.5)	21.0(10.9–60.9)	29.3(13.4–83.6)	< 0.0001
Creatinine (μmol/L)	97.2 ± 53.0	94.6 ± 48.6	102.5 ± 67.2	107.9 ± 56.6	< 0.0001
Hemoglobin (g/L)	136 ± 17	138 ± 17	133 ± 17	131 ± 17	< 0.0001

Data are presented as mean ± SD, number (percentage), or median (interquartile range)

IC intrinsic capacity, *SBP* systolic blood pressure, *DBP* diastolic blood pressure, *CKD* chronic kidney disease, *OHA* oral hypoglycemic agents, *ARB* angiotensin receptor blocker, *HDL* high-density lipoprotein, *LDL* low-density lipoprotein, *eGFR* estimated glomerular filtration rate, *UACR* urinary albumin-to-creatinine ratio

high risk category of CKD, including IC score 0 and normal weight, IC score 0 and moderate and severe obesity, IC score 1–5 and normal weight, and IC score 1–5 and moderate and severe obesity. In univariate analysis, the patients with an IC score 0 and moderate and severe obesity had a 1.90-fold higher KDIGO moderately increased risk to very high risk category of CKD (OR = 1.90; 95% CI 1.35–2.69, p = 0.0003) than those without. In addition, the patients with an IC score 1–5 and normal weight had a 1.69-fold higher moderately increased risk to very high risk of KDIGO CKD risk category (OR = 1.69; 95% CI 1.29–2.23, p = 0.0002) than those without. Moreover, the

Tang *et al. Diabetology & Metabolic Syndrome*   (2023) 15:1

Page 6 of 10

Table 2 Odds ratio (ORs) of KDIGO moderately increased risk to very high risk category of chronic kidney disease according to intrinsic capacity score

Variables	Chronic kidney disease risk stage[a]			p-value
	Moderate risk to very high risk group	Low risk group	OR (95%CI)	
IC score				
Score 0	736 (48.3%)	789 (51.7%)	1.00 (reference)	
Score 1	366 (55.9%)	289 (44.1%)	1.36 (1.13–1.63)	0.001
Score ≥ 2	213 (70.5%)	89 (29.5%)	2.57 (1.97–3.36)	< 0.0001
P for trend			< 0.0001	

IC intrinsic capacity, *OR* odds ratio, *CI* confidence interval

[a] CKD risk stage was defined according to the 2012 KDIGO definition [22]

Table 3 Logistic regression of the association of intrinsic capacity score with KDIGO moderately increased risk to very high risk category of chronic kidney disease

|	Model 1	Model 2	Model 3
Variables	OR (95%CI) p-value	OR (95%CI) p-value	OR (95%CI) p-value
IC score			
0	Ref	Ref	Ref
1	1.36 (1.13–1.63) 0.001	1.21 (1.00–1.46) 0.049	1.12 (0.92–1.37) 0.271
≥ 2	2.57 (1.97–3.36) < 0.0001	1.82 (1.38–2.42) < 0.0001	1.76 (1.31–2.37) 0.0002

OR odds ratio, *CI* confidence interval, *IC* intrinsic capacity

Model 1: Univariate logistic regression analysis

Model 2: Adjusted for age, gender

Model 3: Adjusted for age, gender, diabetes duration, smoking status, body mass index, systolic blood pressure, diastolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, fasting sugar

patients with an IC score 1–5 and moderate and severe obesity had a 3.12-fold higher moderately increased risk to very high risk of KDIGO CKD risk category (OR = 3.12; 95% CI 2.14–4.60, p < 0.0001) than those without (data not shown). In multivariate analysis, the patients with an IC score 0 and moderate and severe obesity had a 1.64-fold higher moderately increased risk to very high risk of KDIGO CKD risk category (OR = 1.64; 95% CI 1.12–2.39, p = 0.011) than those without. Furthermore, the patients with an IC score 1–5 and normal weight had a 1.38-fold higher moderately increased risk to very high risk of KDIGO CKD risk category (OR = 1.38; 95% CI 1.03–1.86, p = 0.034) than those without. Moreover, the patients with an IC score 1–5 and moderate and severe obesity had a 2.71-fold higher moderately increased risk to very high risk of KDIGO CKD risk category (OR = 2.71; 95% CI 1.82–4.10, p < 0.0001) than those without (Fig. 1). The RERI, API, SI, and measure of multiplicative interaction for risk ratios were 0.695, 0.256, 1.683, and 1.200, respectively. The RERI > 0, API > 0, SI > 1, or a measure of multiplicative interaction for risk ratios > 1 suggested that there may be a synergistic interaction between IC score 1–5 and moderate

Fig. 1 Interaction schematic diagram between moderate and severe obesity (OB) and intrinsic capacity (IC) score on KDIGO moderately increased risk to very high risk category of chronic kidney disease after adjusting for multiple confounders

and severe obesity on the risk of KDIGO moderately increased risk to very high risk category. In addition, the API was 0.256 after adjusting for all confounders, indicating that the proportion of risk of KDIGO moderately

Tang *et al. Diabetology & Metabolic Syndrome* (2023) 15:1

Page 7 of 10

increased risk to very high CKD risk category that may have been caused by the interaction of IC score 1–5 and moderate and severe obesity was 25.6% in the patents with a KDIGO moderately increased risk to very high risk category of CKD.

Discussion

In this study, we found that IC score was related to and had a synergistic interaction with obesity on the KDIGO moderately increased risk to very high risk category of CKD in diabetic patients aged ≥ 65 years. IC is a novel concept of healthy aging introduced by the WHO to help develop public health strategies in response to the aging population, as adults older than 60 years are expected to account for 12% to 22% of the global population (approximately 2 billion people) by 2050 (https://www.who.int/news-room/fact-sheets/detail/ageing-and-health). Most recent studies using IC score have focused on frailty, physical resilience and dementia, and rarely on other chronic diseases [17, 29]. Older populations have more comorbidities, which may impair renal function. In this study, we found that the IC score was very sensitive, as even a score of 1 was associated with an increased KDIGO CKD risk staging, and this association persistent after adjustments using logistic regression analysis (Table 3).

We found that IC score was associated with age, female sex, hypertension and obesity status, and a higher IC impairment score was associated with higher BMI, HbA1c, fasting glucose, UACR, creatinine levels, and the use of insulin and angiotensin receptor blockers, and lower eGFR and hemoglobin levels than those with an IC score of 0 or 1 (Table 1). Associations between IC score with demographic characteristics and metabolic control profiles have seldom been described, although a recent study reported that dyslipidemia and not hypertension status was associated with IC score [30, 31]. Most previous studies on IC have focused on interactions among chronic diseases, self-care capacity and social engagement, but not on disease progression or organ function. Two studies reported that impaired IC may be related to renal function and elevated heart failure markers [15, 32], and two other studies reported that impaired renal function was associated impaired mobility and poor nutrition [31, 33]. Therefore, it is important and reasonable to investigate and clarify the associations and interactions between IC score and the risk of renal function impairment, demographic characteristics and metabolic control profiles. The detailed pathogenetic mechanisms between IC and metabolic derangement are discussed below.

The most important finding of this study is the synergistic interaction of IC score and obesity on the KDIGO moderately increased risk to very high risk category of CKD after analyzing multiple interactions for risk ratios (Fig. 1). Several recent studies have reported that obesity is associated with older age and increased rates of frailty and mobility, and that this impairs the patient's quality of life [34]. In 2000, Baumgartner termed the phrase sarcopenic obesity [35], and it has been shown to be especially prevalent and associated with many adverse health conditions in older adults [36]. Sarcopenic obesity is defined as the combination of obesity with low muscle mass and strength [35]. Although it can be caused by age-related changes in body composition [37], several pathways have also been proposed, including a sedentary lifestyle with less physically activity [38], higher inflammation status [39], insulin resistance [40], lower growth hormone and testosterone levels [41, 42], relative malnutrition [43], and poor psychological status [44], all of which occur in older patients.

In a literature review, sarcopenic obesity was associated with frailty among older adults [45], and with the risk of coronary artery disease and all-cause mortality [46, 47]. Recent studies have further shown an association between sarcopenic obesity and chronic renal disease, especially in those with diabetes-related renal impairment [48]. This may explain why insulin resistance, the over-expression of adipokines, and inflammation processes have been associated with obesity and CKD progression [49–53]. Taken together with frailty, it is reasonable that all of these adverse conditions could impair IC and aggravate the deterioration in renal function. Our study provides further information to support that obesity with pre-frailty is associated with the pathogenesis of CKD.

The interactions among muscle wasting, obesity and diabetic nephropathy are unclear. Advanced glycosylated end products (AGEs) have been associated with hyperglycemia, muscle wasting, and impaired renal function in vivo and in vitro [54], In addition, insulin resistance, oxidative stress, inflammation, uremic toxin toxicity, metabolic acidosis, vitamin D deficiency and protein energy wasting occur in patients with diabetic nephropathy, and they also result in muscle loss and abnormal fat deposition in CKD patients [48]. Taken together, these findings show that it is important to detect and evaluate sarcopenic obesity to allow for the more intensive management of diabetes and renal dysfunction in older patients.

Most of the current strategies to prevent the complications of diabetic nephropathy still focus on preventing hyperglycemia, the early diagnosis of kidney disease, and antihypertensive treatment to reduce renin-angiotensin system activity [48]. To reduce complications and disability directly or indirectly caused by diabetes, the American Diabetes Association has

Tang *et al. Diabetology & Metabolic Syndrome*   (2023) 15:1

Page 8 of 10

also launched numerous projects, such as the Diabetes Self-Management Education and Support (DSMES) and ADCES7 Self-Care Behaviors™ to help clinical physician and patients to monitor clinical, psychosocial and behavioral aspects of diabetes [55, 56]. However, none of these focus on the evaluation or detection of sarcopenic obesity-related CKD in diabetic patients.

Rapid and accessible assessment tools to evaluate the health and physical condition of older adults are needed, as not everyone can access medical facilities or afford the cost of biochemical and imaging examinations. Healthy aging is a process of developing and maintaining functional ability that enables well-being in old age. IC considers both physical and mental abilities by determining the functional ability combined with environmental factors and their interaction (https://apps.who.int/iris/handle/10665/ 186463), and it has been proven that using IC is more effective to assess older populations than focusing on specific diseases or biomarkers [15]. In this study, we applied the IC concept to older diabetic patients, and found that impaired IC combined with obesity could further screen out patients with KDIGO moderately increased risk to very high risk category of CKD even before changes in UCAR, eGFR and creatine levels, which are used to evaluate renal function and early CKD clinically.

There are still some limitations to this study. First, we lacked data on inflammation, adipocytokines and other specific kidney injury markers, and further investigations are warranted to investigate their association with IC and CKD progression. Second, due to case number limitation, although the impairment of IC with even an IC score of 1 showing a significant association with the KDIGO moderately increased risk to very high risk category of CKD, further evaluations are needed to clarify which components of IC impairment have the strongest effects. Third, the current observation is a preliminary cross-sectional association study, and further investigations are needed to examine the long-term predictive ability of IC score on the progression of CKD.

Conclusions

This is the first study to show that IC impairment was associated with the KDIGO moderately increased risk to very high risk category of CKD, and that obesity status further interacted and synergistically increased the KDIGO categories of risk of CKD among older diabetic patients. Earlier interventions for IC impairment and obesity should be performed in this population to help prevent CKD.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate
The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committees of Pingtung Christian Hospital and E-Da Hospital with a Clinical Trial Approval Certificate from Pingtung Christian Hospital on 16th December 2005 and E-Da Hospital Institutional Review Board number EMRP-108-111 and EMRP-109-109. All experiments were carried out in accordance with the approved guidelines. Written informed consent was obtained from all subjects involved in the study.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no financial and non-financial competing interests.

Author details
[1]Division of Cardiology, Department of Internal Medicine, Taipei Veterans General Hospital, Yuli Branch, Hualien 98142, Taiwan. [2]Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan. [3]Division of Cardiology, Department of Internal Medicine, E-Da Hospital, Kaohsiung 82445, Taiwan. [4]School of Medicine, College of Medicine, I-Shou University, Kaohsiung 82445, Taiwan. [5]Health Promotion Administration, Ministry of Health and Welfare, Taipei 10320, Taiwan. [6]Lee's Endocrinologic Clinic, No. 130 Min-Tzu Rd, Pingtung 90000, Taiwan.

References

1. World Health Organization. World report on ageing and health. World Health Organization (2015). https://apps.who.int/iris/handle/10665/186463.
2. Glovaci D, Fan W, Wong ND. Epidemiology of diabetes mellitus and cardiovascular disease. Curr Cardiol Rep. 2019;21:21.

3. George PP, Lun P, Ong SP, Lim WS. A rapid review of the measurement of intrinsic capacity in older adults. J Nutr Health Aging. 2021;25:774–82.
4. Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12:2032–45.
5. Jitraknatee J, Ruengorn C, Nochaiwong S. Prevalence and risk factors of chronic kidney disease among type 2 diabetes patients: a cross-sectional study in primary care practice. Sci Rep. 2020;10:6205.
6. Hannan M, Ansari S, Meza N, et al. CRIC study investigators; chronic renal insufficiency cohort (CRIC) study investigators. risk factors for CKD progression: overview of findings from the CRIC study. Clin J Am Soc Nephrol. 2021;16:648–59.
7. Wasung ME, Chawla LS, Madero M. Biomarkers of renal function, which and when? Clin Chim Acta. 2015;438:350–7.
8. Leung E, Wongrakpanich S, Munshi MN. Diabetes management in the elderly. Diabetes Spectr. 2018;31:245–53.
9. Meneilly GS, Tessier D. Diabetes in elderly adults. J Gerontol A Biol Sci Med Sci. 2001;56:M5-13.
10. Longo M, Bellastella G, Maiorino MI, Meier JJ, Esposito K, Giugliano D. Diabetes and aging: from treatment goals to pharmacologic therapy. Front Endocrinol. 2019;10:45.
11. Ben-Shlomo Y, Cooper R, Kuh D. The last two decades of life course epidemiology, and its relevance for research on ageing. Int J Epidemiol. 2016;45:973–88.
12. Belsky DW, Caspi A, Houts R, et al. Quantification of biological aging in young adults. Proc Natl Acad Sci. 2015;112:E4104–10.
13. Chatterji S, Byles J, Cutler D, Seeman T, Verdes E. Health, functioning, and disability in older adults–present status and future implications. Lancet. 2015;385:563–75.
14. González-Bautista E, de Souto BP, Virecoulon Giudici K, Andrieu S, Rolland Y, Vellas B. Frequency of conditions associated with declines in intrinsic capacity according to a screening tool in the context of integrated care for older people. J Frailty Aging. 2021;10:94–102.
15. Zhou Y, Ma L. Intrinsic capacity in older adults: recent advances. Aging Dis. 2022;13:353–9.
16. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012;35(1):S64-71.
17. Ma L, Chhetri JK, Zhang Y, et al. Integrated care for older people screening tool for measuring intrinsic capacity: preliminary findings from ICOPE Pilot in China. Front Med. 2020;7: 576079.
18. Zheng W, McLerran DF, Rolland B, et al. Association between body-mass index and risk of death in more than 1 million Asians. N Engl J Med. 2011;364:719–29.
19. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004;363:157–63.
20. Health Promotion Administration, Ministry of Health and Welfare. Taiwan's Obesity Prevention and Management Strategy. 1st edn, 1, 55 (Health Promotion Administration, Ministry of Health and Welfare, 2018). https://ghdx.healthdata.org/organizations/health-promotion-administration-ministry-health-andwelfare-taiwan.
21. Kong X, Ma Y, Chen J, et al. Chinese eGFR investigation collaboration. evaluation of the chronic kidney disease epidemiology collaboration equation for estimating glomerular filtration rate in the Chinese population. Nephrol Dial Transpl. 2013;28:641–51.
22. Levin A, Stevens PE, Bilous RW, et al. Kidney disease: improving global outcomes (KDIGO) CKD work group KDIGO clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2012;2013(3):1–150.
23. Wang CP, Lu YC, Hung WC, et al. Inter-relationship of risk factors and pathways associated with chronic kidney disease in patients with type 2 diabetes mellitus: a structural equation modelling analysis. Public Health. 2021;190:135–44.
24. Andersson T, Alfredsson L, Källberg H, Zdravkovic S, Ahlbom A. Calculating measures of biologicalinteraction. Eur J Epidemiol. 2005;20:575–9.
25. Rothman KJ. Modern epidemiology. 1st ed. Boston: Little, Brown; 1986.
26. Hosmer DW, Lemeshow S. Confidence interval estimation of interaction. Epidemiology. 1992;3:452–6.
27. Li R, Chambless L. Test for additive interaction in proportional hazards models. Ann Epidemiol. 2007;17:227–36.
28. Knol MJ, VanderWeele TJ, Groenwold RH, Klungel OH, Rovers MM, Grobbee DE. Estimating measures of interaction on an additive scale for preventive exposures. Eur J Epidemiol. 2011;26:433–8.
29. Gonzalez-Bautista E, de Souto BP, Virecoulon GK, Andrieu S, Rolland Y, Vellas B. Frequency of conditions associated with declines in intrinsic capacity according to a screening tool in the context of integrated care for older people. J Frailty Aging. 2021;10:94–102.
30. Leung AYM, Su JJ, Lee ESH, Fung JTS, Molassiotis A. Intrinsic capacity of older people in the community using WHO integrated care for older people (ICOPE) framework: a cross-sectional study. BMC Geriatr. 2022;22:304.
31. Cheng YC, Kuo YC, Chang PC, et al. Geriatric functional impairment using the integrated care for older people (icope) approach in community-dwelling elderly and its association with dyslipidemia. Vasc Health Risk Manag. 2021;17:389–94.
32. Ma L, Zhang Y, Liu P, et al. Plasma N-terminal Pro-B-type natriuretic peptide is associated with intrinsic capacity decline in an older population. J Nutr Health Aging. 2021;25:271–7.
33. Koppe L, Fouque D, Kalantar-Zadeh K. Kidney cachexia or protein-energy wasting in chronic kidney disease: facts and numbers. J Cachexia Sarcopenia Muscle. 2019;10:479–84.
34. Association of Obesity and Frailty in Older Adults. NHANES 1999–2004. J Nutr Health Aging. 2019;23:138–44.
35. Baumgartner RN. Body composition in healthy aging. Ann N Y Acad Sci. 2000;904:437–48.
36. Stenholm S, Harris TB, Rantanen T, Visser M, Kritchevsky SB, Ferrucci L. Sarcopenic obesity: definition, cause and consequences. Curr Opin Clin Nutr Metab Care. 2008;11:693–700.
37. Ding J, Kritchevsky SB, Newman AB, et al. Health ABC study effects of birth cohort and age on body composition in a sample of community-based elderly. Am J Clin Nutr. 2007;85:405–10.
38. LaMonte MJ, Blair SN. Physical activity, cardiorespiratory fitness, and adiposity: contributions to disease risk. Curr Opin Clin Nutr Metab Care. 2006;9:540–6.
39. Schrager MA, Metter EJ, Simonsick E, et al. Sarcopenic obesity and inflammation in the InCHIANTI study. J Appl Physiol. 1985;2007(102):919–25.
40. Goodpaster BH, Krishnaswami S, Resnick H, et al. Association between regional adipose tissue distribution and both type 2 diabetes and impaired glucose tolerance in elderly men and women. Diabetes Care. 2003;26:372–9.
41. Waters DL, Qualls CR, Dorin RI, Veldhuis JD, Baumgartner RN. Altered growth hormone, cortisol, and leptin secretion in healthy elderly persons with sarcopenia and mixed body composition phenotypes. J Gerontol A Biol Sci Med Sci. 2008;63:536–41.
42. Schaap LA, Pluijm SM, Smit JH, et al. The association of sex hormone levels with poor mobility, low muscle strength and incidence of falls among older men and women. Clin Endocrinol. 2005;63:152–60.
43. Houston DK, Nicklas BJ, Ding J, et al. Health ABC study dietary protein intake is associated with lean mass change in older, community-dwelling adults: the health, aging, and body composition (health ABC) study. Am J Clin Nutr. 2008;87:150–5.
44. Hamer M, Batty GD, Kivimaki M. Sarcopenic obesity and risk of new onset depressive symptoms in older adults: english longitudinal study of ageing. Int J Obes. 2015;39:1717–20.
45. Jarosz PA, Bellar A. Sarcopenic obesity: an emerging cause of frailty in older adults. Geriatr Nurs. 2009;30:64–70.
46. Aubertin-Leheudre M, Lord C, Goulet ED, Khalil A, Dionne IJ. Effect of sarcopenia on cardiovascular disease risk factors in obese postmenopausal women. Obesity. 2006;14:2277–83.
47. Rantanen T, Harris T, Leveille SG, et al. Muscle strength and body mass index as long-term predictors of mortality in initially healthy men. J Gerontol A Biol Sci Med Sci. 2000;55:M168–73.
48. Chen SH, Liang YJ. The role of lifestyle intervention, in addition to drugs, for diabetic kidney disease with sarcopenic obesity. Life. 2022;12:380.
49. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest. 2000;106:473–81.
50. Spoto B, Pisano A, Zoccali C. Insulin resistance in chronic kidney disease: a systematic review. Am J Physiol Renal Physiol. 2016;311:F1087–108.
51. Rüster C, Wolf G. Adipokines promote chronic kidney disease. Nephrol Dial Transpl. 2013;28(4):8–14.

52. Zorena K, Jachimowicz-Duda O, Ślęzak D, Robakowska M, Mrugacz M. Adipokines and obesity potential link to metabolic disorders and chronic complications. Int J Mol Sci. 2020;21:3570.
53. Akchurin OM, Kaskel F. Update on inflammation in chronic kidney disease. Blood Purif. 2015;39:84–92.
54. Yabuuchi J, Ueda S, Yamagishi SI, et al. Association of advanced glycation end products with sarcopenia and frailty in chronic kidney disease. Sci Rep. 2020;10:17647.
55. Powers MA, Bardsley J, Cypress M, et al. Diabetes self-management education and support in type 2 diabetes: a joint position statement of the american diabetes association, the American association of diabetes educators, and the academy of nutrition and dietetics. Diabetes Care. 2015;38:1372–82.
56. Kolb L. Association of diabetes care and education specialists an effective model of diabetes care and education: the ADCES7 self-care behaviors™. Sci Diabetes Self Manag Care. 2021;47:30–53.

Publisher's Note